Shameer Marvan K’s Post

𝗜𝗻𝗱𝗶𝗮’𝘀 𝗣𝗵𝗮𝗿𝗺𝗮 𝗘𝘅𝗽𝗼𝗿𝘁 𝗕𝗼𝗼𝗺: 𝗣𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 India is a leading player in the global pharmaceutical market, valued at around $42 billion and projected to reach $65 billion by 2024. With $24.6 billion in exports in 2021-22 alone, India’s pharma growth is fueled by high-quality standards, cost-effective production, and a strong demand for generics. 𝗧𝗼𝗽 𝗜𝗻𝗱𝗶𝗮𝗻 𝗣𝗵𝗮𝗿𝗺𝗮 𝗘𝘅𝗽𝗼𝗿𝘁𝗲𝗿𝘀 𝗔𝗰𝘁𝗶𝘇𝗮 𝗣𝗵𝗮𝗿𝗺𝗮 – Exports to over 150 countries, valued at nearly $1 billion. 𝗦𝘂𝗻 𝗣𝗵𝗮𝗿𝗺𝗮 – Known for complex generics, with exports worth $1.1 billion. 𝗗𝗿. 𝗥𝗲𝗱𝗱𝘆’𝘀 – Exported $1.2 billion in quality generics. 𝗖𝗶𝗽𝗹𝗮 𝗟𝘁𝗱. – Leading in respiratory meds, reaching $1.3 billion in exports. 𝗟𝘂𝗽𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 – Strong in the U.S. market, exporting $1.1 billion. 𝗙𝘂𝘁𝘂𝗿𝗲 𝗧𝗿𝗲𝗻𝗱𝘀 𝘁𝗼 𝗪𝗮𝘁𝗰𝗵 Rising Demand for Generics in developed markets. Expansion into Emerging Markets like Africa and Latin America. Investment in R&D and advanced tech to stay competitive. Focus on Quality & Compliance for a global edge. As Indian pharma companies continue to innovate and expand, they’re meeting global health needs while driving economic growth. #Actiza #Pharmaceuticals #Healthcare #Pharmaexport

👋 👋 👋 #Indian #pharma #industry projected to reach $130 billion by 2030 say experts 👉 https://lnkd.in/g6pt7qhe 👋 👋 👋 Quoting: 🔴 Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047 🔴By 2030, we expect our exports to grow significantly, with 70% directed to #Europe and the U.S. Our industry’s impact is enormous 🔴Indian pharmaceuticals contribute $8 billion annually to the U.S. healthcare system, saving patients more than $1.5 trillion 🔴With growing capabilities in #AI, #machinelearning, and #biologics, India is poised to become the world’s leading pharmaceutical #hub, targeting a $1 #trillion industry by 2047 🔴low #manufacturing #cost, which is 30%-35% lower than in the U.S. and #Europe, cost-efficient R&D at 87% less than developed markets and an abundant pool of skilled #labour 🔴India now ranks third globally in pharmaceutical production by volume and 14th by value, contributing approximately 1.72% to the nation’s #GDP. 🔴India is among the top 12 #global #biotechnology destinations and the third largest in the #Asia-Pacific region #india #pharma #drug #billion #industry #leadership #research #development #economy #production #talent #quality

Big Opportunity in Pharma Sector! 💊🚀 India's pharma sector is set to hit a $57 billion market size by FY25, with profit margins improving by 100-150 basis points. Here's why you should take notice: ✅ Domestic growth: 8-9% steady growth, consistent export growth of 6-7% ✅ US patent expirations (2024-28): A significant opportunity for generic drug companies ✅ New segments: Companies targeting booming markets like anti-obesity drugs, projected to reach $100 billion by 2030! Despite challenges, this sector is entering a strong growth phase. Research now and prepare your pharma portfolio! 💬 Comment below: Which pharma stock do you have in your portfolio? 👉 Follow us for more sector analysis! [Pharma sector, Healthcare, Indian Pharma Sector, Pharma growth, Indian Market, Market Insights] #pharmastocks #pharmasector #indianpharma #stockmarket #smartinvesting #marketinsights #financialgrowth #wealthbuilding #choice #bharosekichoice

🌍✨ India’s Pharma Ecosystem: A Magnet for Global Innovation ✨🌍 India stands as a powerhouse in the global pharmaceutical industry. Here’s my thought on why global companies should look towards India for investment: Market Leadership & Growth: India is the third-largest producer of pharmaceuticals by volume and the 14th largest by value. It supplies over 50% of global demand for various vaccines and 40% of generic demand in the US. The industry is projected to grow to USD 120-130 billion by 2030. R&D Capabilities & Collaborations: India has a strong network of more than 3,000 pharma companies and 10,500 manufacturing units. The partnerships between global companies, local firms, academic institutions, and research organizations enhance innovation and development. Policy Support and Mission: The Indian government offers various incentives such as the Production Linked Incentive (PLI) Scheme. The government aims to make India a global leader in end-to-end drug manufacturing. Cost Efficiency: The country offers significant cost advantages in terms of production and labor, which allows companies to produce high-quality medicines, vaccines etc at lower costs. Strong Regulatory Framework: India's pharmaceutical sector ensures high quality and safety standards through the Central Drugs Standard Control Organization (CDSCO) and compliance with international standards like the US FDA and EMA. The pharma companies can join the journey towards a healthier world with India's thriving pharma industry! #pharma #india #growth Image source: Economics Time Data Source: Investing India Web

Reading about the Indian pharmaceutical industry's robust growth trajectory is always a matter of pride. I think any one of you working within Indian pharma would feel the same. India's pharma market value doubling to $120 bn in only 6 years is commendable by any means. So where is this growth expected from? No, not exports. We're talking about the growth of our Indian domestic market here. Have a read through the article, 1. Global pharma companies investing locally in R&D, manufacturing and cutting edge technology 2. And surely, an increasing population size and larger burden of disease, opening 'opportunities' for new and specialty drugs If I may, l'd add a 3rd reason of my own. De-risking from China, or if you sugar coat it - it's termed the China +1 strategy. But before we worry about China, it's better to focus on our own ambitions and capabilities. Ambitions wise, we're up there at the top. No worries for that. How about capabilites? This really is the tricky part. We do have a few hurdles of our very own in comparision to other countries. Nothing impossible though. But still quite complex to navigate.

Building a Healthier Future: The Unwavering Dedication of India's Pharma Industry (2020-2030) With a rise in #domestic manufacture, the #pharmaceutical industry in India is undergoing a tremendous transition. Companies are growing along the whole production chain, from long-standing participants like #Piramal Alternatives investing in #Biodeal Pharmaceuticals to recent arrivals like #Rusan Pharma constructing new API facilities. The emphasis on completed formulations (#Cadila Pharmaceuticals, #Aurobindo Pharma) as well as active pharmaceutical ingredients (APIs) suggests a thorough attempt to build an independent pharmaceutical ecosystem. There are probably a number of reasons behind this surge in home manufacturing: • #Government #Incentives: Companies are being encouraged to establish manufacturing bases in #India by initiatives such as the #PLI scheme, the progress of which is demonstrated by the completion of multiple greenfield units. • Expanding local Market: There is a significant local market for medicines in India due to the country's growing #population and rising healthcare awareness. • Good Workforce: The pharmaceutical business benefits greatly from India's youthful and talented workforce population. This "Make in India" strategy's success depends on several important factors: • Quality Assurance: In order for Indian pharmaceuticals to compete internationally, they must uphold strict quality control procedures. • Global Market Competition: In order to increase its market share, India must successfully compete with existing competitors. • Research and Development: To create novel medications and stay ahead of the curve, a strong #R&D environment is necessary. The efficacy of PLI schemes is indicated by the continuous investments made in the industry, such as the new API facility by #Rusan Pharma and the participation of #Pilamal Alternatives in #Biodeal Pharmaceuticals. Long-Term Sustainability: India's capacity to handle the a fore mentioned issues will determine how long this trend lasts. By the 2030s, sustained government assistance combined with R&D investments from the business sector might catapult India into the forefront of the global pharmaceutical industry.

#BiotechnologyindustryinIndia India is among top 12 destinations for biotech worldwide and 3rd largest destination for biotech in Asia Pacific. India is one of the biggest suppliers of low cost drugs and vaccines in the world. India also leads in biosimilars, with the most number of biosimilars approved in the domestic market. India accounts for 60% of global vaccine production making it the largest low cost vaccine producer in the world.India is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume. India conribute 90% of vaccines and pharmaceuticals to the world. India's biotech industry clocked USD 92.3 billion in 2022, and the vision is to achieve USD 150 billion by 2025 and USD 300 billion by 2030, as per Biotechnology Industry Research Assistance Council ( BIRAC).

Indian pharma industry eyes 9% annual growth on strong domestic and export markets, says report #IndianPharma #PharmaGrowth #ExportMarkets #DomesticMarkets #PharmaIndustry #AnnualGrowth #MarketReport #IndianEconomy #PharmaExports #IndustryInsights

𝗗𝗼 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄? 𝗧𝗵𝗲 𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝗰𝗲 𝗼𝗳 𝗚𝗲𝗻𝗲𝗿𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗜𝗻𝗱𝗶𝗮𝗻 𝗣𝗵𝗮𝗿𝗺𝗮 𝗠𝗮𝗿𝗸𝗲𝘁 India's pharmaceutical industry has grown tremendously, largely due to its role as a leading producer of generic medicines. Here's why generic medicines are crucial: 𝗖𝗼𝘀𝘁 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: Generic drugs are, on average, 80-85% cheaper than branded counterparts, allowing wider access to essential medications. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗵𝗮𝗿𝗲: India supplies around 20% of the global generic medicines and is the world’s largest provider of generics by volume. 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗥𝗲𝗮𝗰𝗵: With 65% of the Indian population residing in rural areas, generic medicines make healthcare accessible to these underserved communities. 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗖𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻: The Indian generic drug market was valued at around $25.9 billion in 2023 and is expected to grow to $30 billion by 2025. 𝗚𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: Initiatives like the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) promote the use of generics by setting up stores across India that offer affordable medicines. 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀: India has the highest number of FDA-approved generic drug manufacturing facilities outside of the U.S., ensuring high-quality products. 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗜𝗺𝗽𝗮𝗰𝘁: The production of generics consumes fewer resources and results in less environmental impact compared to developing new drugs from scratch. #Actiza #Pharmaexport #Pharmamanufacturer #Healthcare

🇮🇳🚀 India's Pharmaceutical Industry : An emerging global powerhouse 🚀🇮🇳 The U.S. Biosecure Act will galvanise India's pharmaceutical metamorphosis, unlocking a remarkable growth potential. Contract manufacturing is projected to double within three years, reaching a $44.63 billion market by 2029 with a 14.67% CAGR. However, India's prowess extends beyond mere figures. We are a bastion of ingenuity, adept at navigating the complex serialization, track and trace, and stringent regulatory frameworks. This positions us as a potential vanguard, poised to redefine the apotheosis of global pharmaceutical standards. AltiusHub is determined to be the catalyst driving this evolution. Our end-to-end SaaS solution empowers Indian pharma to achieve unparalleled compliance and spearhead the industry's advancement. The world seeks pharmaceutical leadership. India answers the call. 🌍 #IndianPharma #BiosecureAct #MadeInIndia #PharmaLeadership #AltiusHub Ministry Of Chemicals & Fertilizers, Ministry of Health and Family Welfare, Government of India, AltiusHub